Antibody is a specific immunoglobulin produced by the immune system when the body is stimulated by antigen, which plays a significant role in host defense, the recognition and elimination of the foreign pathogen, and autogenous immune surveillance. The emergence of hybridoma technology in 1975 laid the foundation for the development and flourishing of monoclonal antibodies (mAbs) both in the laboratory and clinical. Later in 1986, the first therapeutic murine mAb was approved. Since then a variety of therapeutic antibody drugs developed by different antibody technologies come into sight, such as engineered mAbs, antibody-drug conjugates, antibody fusion proteins, single domain antibodies, etc.
Fig.1 Critical steps in single-cell B-cell cloning workflows.1
B cell sorting is a new antibody technology that develops mAbs by directly isolating antibody-secreting B cells from an immunized host. It is capable of not only high-throughput screening and producing fully human mAbs or natural mAbs but also identifying rare antibodies with the biological activity of interest and favorable manufacturing properties. Moreover, this single B cell antibody technology can be applied for the antibody development for a diversity of species in a time-saving manner, requiring trace lymphatic samples. To discover unique antibodies in a short period for our worldwide clients, Creative Biolabs currently has pushed out a state-of-the-art B cell sorting platform to provide comprehensive Native™ antibody development services for a wide range of species, including:
With years of research and development experience in monoclonal antibody production, Creative Biolabs is pleased to apply our powerful B cell sorting platform to provide a comprehensive range of Native™ antibody development services for various species and targets, covering:
Please feel free to contact us. Our experienced technicians will give you the most detailed answers to your questions.
Reference
